The prevalence and development of microsatellite instability (MSI) and underlying mismatch repair (MMR) deficiency in the carcinogenesis of adenocarcinomas of the papilla of Vater and their precursor lesions are not well established. We analyzed 120 ampullary adenomas (31 pure adenomas and 89 carcinoma-associated adenomas) and 170 pure adenocarcinomas for MSI, immunohistochemical expression of MMR proteins and specific histopathologic features. The most common histologic subtype was intestinal (46.5%), followed by pancreatobiliary (23.5%), poorly differentiated adenocarcinomas (12.9%), intestinal-mucinous (8.2%), and invasive papillary carcinomas (5.3%). Eight of 89 adenomas (9%) and 15/144 carcinomas (10%) showed high microsatellite instability (MSI-H), 10/89 adenomas (11%) and 5/144 carcinomas (4%) showed low microsatellite instability (MSI-L), and 71/89 adenomas (80%) and 124/144 carcinomas (86%) were microsatellite stable (MSS). MSI analysis from carcinomas contiguous with an adenomatous component (n = 54) exhibited concordant results in 6/8 (75%) MSI-H and 42/46 (91.3%) MSS tumors. Of 14 carcinomas with MSI-H, 7 showed loss of MLH1 and 5/6 (83%) MLH1 promoter methylation, and 2 carcinomas showed simultaneous loss of MSH2 and MSH6. Two carcinomas and 3 adenomas with MSI-H revealed exclusive loss of MSH6. MSI-H cancers were significantly associated with intestinal mucinous subtype (P<0.001), high tumor grade (P = 0.003), expansive growth pattern (P = 0.044), and marked lymphoid host response (P = 0.004). Patients with MSI-H carcinoma had a significantly longer overall survival (P = 0.0082) than those with MSI-L or MSS tumors. Our findings indicate that the MSI-phenotype is an early event, which develops at the stage of adenoma and is reliably detectable in the precursor lesion. The MMR deficient molecular pathway of carcinogenesis is associated with a histopathologic phenotype in ampullary cancer, similar to the one that has been well described in colon cancer.
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Key Words: ampullary neoplasm, histomorphology, molecular characteristics, prognostic factor, microsatellite instability, MSI, long-term survival C arcinomas of the papilla of Vater, defined as the junction of the biliary and pancreatic ducts within the duodenum, account for approximately 6% to 20% of all periampullary tumors and represent approximately 10% to 50% of cancers resected via pancreaticoduodenectomy. 27, 35 These tumors have a better prognosis after curative resection compared with pancreatic head carcinoma or extrahepatic bile duct carcinoma. The favorable prognosis is thought to be due to early clinical presentation with obstructive jaundice 81 and subsequently histologic diagnosis by biopsy at the time of endoscopic retrograde cholangiopancreatography. However, there seem to be biologic differences as well. 15, 18, 87 Nevertheless, the 5-year survival rate ranges from 21% to 64%. 23, 74, 78 The tumors often contain adenomatous tissue, which is considered to be a precursor of the carcinoma. 41, 75, 77 An adenoma-carcinoma sequence with stepwise accumulation of genetic alterations similar to colorectal cancer has therefore been proposed for tumors of the ampulla of Vater. 20, 34, 41, 59, 77, 89 However, to date there are still very limited data on molecular alterations in ampullary tumors. 4, 6, 54, 55, 68 As the ampulla of Vater is lined by epithelial cells that derive either from the biliary and pancreatic or the duodenal lineage, ampullary adenocarcinomas can exhibit different histologic subtypes, specifically an intestinal and an pancreatobiliary type. 32, 45 Ampullary adenocarcinomas are also included in the broad extracolonic tumor spectrum 2, 47 of hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, in which more than 90% of the carcinomas show microsatellite instability (MSI) due to a loss of mismatch repair (MMR) function. 1, 61 However, this specific type of genetic instability characterized by length alterations within simple repeated sequences, 37 also occurs in a subset of sporadic cancers. 13, 19, 22, 29, 33, 50 Colorectal carcinomas (CRCs) with high-frequency MSI (MSI-H) exhibit fundamental differences in clinical, pathologic, molecular, and histomorphologic characteristics when compared with microsatellite stable (MSS) tumors and tumors with low-frequency MSI (MSI-L). 38 Previous studies describe MSI in approximately 12.5% to 22.2% of ampullary carcinomas. However, only small series of tumors were investigated (summarized in Table 1 ) and the prognostic value of MSI in these tumors is not entirely clear. In addition, there are no data on the prevalence and development of MMR deficiency in the early neoplastic lesions-pure adenomas or adenomas contiguous with invasive carcinoma. In the present study, we investigated a large series of 290 unselected ampullary adenomas and adenocarcinomas for MSI status, MMR protein (MLH1, MSH2, MSH6) expression, histomorphologic features, prognostic factors, and overall survival. Furthermore, our aim was to investigate whether MSI-H and loss of MMR proteins are already detectable in pure adenomas and concordantly detectable in both adenoma and associated carcinoma to prove the hypothesis that MMR deficiency and the resulting MSI is an early event in ampullary carcinogenesis.
MATERIALS AND METHODS

Patient Characteristics and Histomorphologic Evaluation
Between 1985 and 2005, tissue samples of 120 ampullary adenomas and 170 carcinomas with unequivocal origin from the anatomic structures forming the ampulla of Vater were obtained by surgical or endoscopic excision, respectively (161 Whipple resection specimens, 26 transduodenal local resections, and 13 endoscopic snare resections). Only biopsy material was available for one of the ampullary cancers as the tumor was not resected. Formalin-fixed, paraffin-embedded tissue blocks (containing non-neoplastic intestinal or gastric mucosa and representative tumor tissue) were retrieved from the archives of the Institute of Pathology, University of Regensburg (Germany), the Institute of Pathology, Nurnberg (Germany), the Institute of Pathology, Kassel (Germany), the Anatomic Pathology Unit, Department of Human Morphology, University of Insubria, Varese (Italy), the Department of Pathology, University of Kiel (Germany), and the Institute of Pathology, University Hospital, Basel (Switzerland). All tumors were staged using the TNM classification for ampullary carcinomas. 82 The clinicopathologic characteristics of patients and tumors are summarized in Supplementary Tables 1  and 2 (Table 1 Histology of all tumors was reviewed by 2 experienced pathologists (L.T. and P.R.) without knowledge of clinical and molecular data. The histopathologic tumor type, the presence of coexisting adenomas, and the degree of dysplasia, the histologic grade, the percentage 30 ) were noted during review. According to the recommendations of the German HNPCC Consortium, 67 TILs were scored semiquantitatively as none, rare (10 TILs/5 high-power fields), or intense (25 TILs/5 high-power fields). The presence or absence of a Crohn's like reaction was scored as 0 or 1, respectively. For a positive score, at least 3 nodular lymphocyte aggregates had to be detectable at low-power view. The presence of germinal centers was not mandatory. All tumors at the ampulla of Vater were classified histologically according to the criteria published by Albores-Saavedra et al. 7 In addition, an intestinalmucinous subtype was defined and characterized by any mucinous differentiation. (Adeno-) squamous carcinomas were excluded. Grade was assigned in accordance with the World Health Organization Classification of Tumors of the Digestive System. 8 Patient data, including history of other primary tumors and family history of cancer and complete follow-up information were obtained through retrospective review of medical records, the regional clinical tumor registries, or by direct contact of the referring physician, and were available for 133 patients (78%) with ampullary carcinoma (follow-up time from the date of surgery up to 164 mo; median, 36 mo). The study was approved by the Institutional Review Board of the institutions involved.
Immunohistochemistry for MSH2, MLH1, and MSH6
To determine the MMR protein status, whole tissue sections of all tumors were subjected to immunohistochemical analysis, as described previously. 33 In brief, 4 mm formalin-fixed paraffin-embedded tissue sections were deparaffinized and immunostained after microwave-based antigen retrieval using the IView DAB Detection Kit on a Ventana Nexes autostainer (Ventana, Tucson, AZ). Less than 1% nuclear staining in the tumor cells in the presence of normal nuclear staining in adjacent lymphocytes and normal epithelial or stromal cells was considered loss of expression of the respective MMR protein.
The immunohistochemical results in tumors classified as highly microsatellite instable (MSI-H) were confirmed at least twice by repeated immunohistochemistry (IHC).
Molecular Analysis
Tumor and corresponding normal DNA was extracted from formalin-fixed paraffin-embedded tissue as described previously. 66 In brief, glass slides with 10-mm sections were deparaffinized and stained with 0.01% methylene blue for approximately 30 seconds. Microdissection of the tumor tissue was carried out with a needle (22- 12, 14, 24, 25 Briefly, PCR amplifications were performed with 50 to 100 ng of purified genomic DNA. Subsequently, amplification products of 6 markers were analyzed by 6.7% polyacrylamide/50% urea gel electrophoresis and visualized by silver staining. D18S61 was evaluated by capillary electrophoresis on an ABI3100 Genetic Analyzer using Gene-Scan2.1 software (Applied Biosystems, Weiterstadt, Germany). All results (gels and fragment patterns) were evaluated independently by 3 observers (P.R., W.D., and A.H.). MSI was defined by the presence of novel bands after PCR amplification of tumor DNA that was not present in PCR products of the paired normal DNA. Tumor samples were included in the MSI analysis only if at least 3 microsatellite loci could be analyzed. Using criteria established for CRC, tumors were classified as highly microsatellite instable (MSI-H) if at least 30% of the markers tested were instable. Low microsatellite instable (MSI-L) and MSS were defined as an MSI frequency of <30% and 0%, respectively.
14,24 Samples were evaluated as uninformative for loss of heterozygosity (LOH) if the normal sample was homozygous or if MSI was present. LOH was defined if the ratio of the 2 alleles in the tumor sample compared with the ratio of the alleles in the normal sample was r0.5 or >2.0. Each paired sample with MSI or LOH was analyzed in a second independent PCR amplification to verify the results.
For the assessment of MLH1 promoter methylation, methylation-specific PCR (MSP) was performed as described recently. 70 Briefly, extracted DNA was subjected to sodium bisulfite modification using the CpGenome DNA modification kit (Chemicon). Modified DNA was subjected to MSP using specific primers for methylated sequences (sense 5 0 -AGCGGATAGCGAT TTTTAACGC and antisense 5 0 -TCTTCGTCCCTCCC TAAAACG) and for unmethylated sequences (sense 5 0 -GAAGAGTGGATAGTGATTTTTAATGT and antisense 5 0 -ATCTCTTCATCCCTCCCTAAAACA), which generates PCR products of 78 and 85 bp, respectively. The reaction volume of 25 mL contained 2 mL of bisulfitemodified DNA, 1 Â PCR buffer, 3 mM MgCl 2 , 12.5 pmol of each primer, 160 mM dNTPs, and 0.5 U of Hot-Goldstar Taq polymerase (Eurogentec, Seraing, Belgium). PCR conditions were as follows: 951C for 10 minutes, 35 cycles of 951C for 1 minute, 601C for 1 minute, and 721C for 1 minute, followed by a final extension step at 721C for 10 minutes. Methylated standard DNA (Intergen) was used as a positive control for methylation, and placenta DNA was used as a negative control. PCR products were electrophoresed on polyacrylamide gels and visualized by silver staining.
Statistical Analysis
Statistical correlation between clinicopathologic, morphologic, immunohistochemical, and molecular parameters was tested using a 2-sided Fisher exact test. Overall survival (OS) time was calculated according to Kaplan-Meier survival curves. OS was measured from the time of surgery and compared patients with or without any of the clinical, pathologic, morphologic, or molecular factors using 2-sided log-rank statistics. The differences were considered to be statistically significant when the P value was <0.05. A stepwise multivariable Cox regression model was adjusted, testing the independent prognostic relevance of the MSI status. The limit for reverse selection procedures was P = 0.1. The proportionality assumption for all variables was assessed with log-negative-log survival distribution functions. All statistical analyses were conducted using the SPSS version 13.0 statistical software program (SPSS, Chicago, IL).
RESULTS
Clinicopathologic and Histopathologic Characteristics
All clinicopathologic and molecular characteristics of the tumors are given in detail in Supplementary Tables  1 and 2 . Of the 170 ampullary carcinomas, the most common histologic subtype was intestinal (n = 79; 46.5%), followed by pancreatobiliary (n = 40; 23.5%), poorly differentiated adenocarcinomas (n = 22; 12.9%), intestinal-mucinous (n = 14; 8.2%), and invasive papillary (n = 9; 5.3%; Figs. 1B-F). Of the intestinalmucinous subtype, 4 (28.6%) showed prominent extracellular mucin (>50% of the tumor, ie, mucinous carcinomas), 10 (71.4%) showed only focal (r50%) extracellular mucin. Additionally, we observed some rare subtypes of adenocarcinomas (1 noninvasive papillary carcinoma and 1 signet ring cell carcinoma) and 1 neuroendocrine small cell carcinoma. Three tumors were histologically not classifiable. These rare and unclassifiable tumors (n = 6) were excluded from the study. Seventy-one (44%) of the remaining ampullary cancers (n = 164) presented at an advanced tumor stage (pT3: n = 60; 37%; pT4: n = 11; 7%) and 90 (56%) were early stage cancers (pT1: n = 28; 17%; pT2: n = 62; 38%). Tumor staging and grading were not available in 3 and 4 cases, respectively. Twenty-three (14%) cancers were well differentiated, 71 (44%) moderately, and 66 (41%) cases poorly differentiated. The mean size of the tumors was 2.3 cm (median 2 cm; range: 0.4 to 4.5 cm). Lymph node metastases were present in 73 (49%) cancers. There were 90 males and 74 females, with a median age of 67 years at diagnosis (range: 44 to 79). An associated adenomatous component was identified in 89 cancers (54%; Fig. 1A ). The majority of these areas of residual adenoma exhibited tubular or tubulopapillary architecture and high-grade dysplasia. Age, sex, lymphatic or vascular invasion, growth pattern, lymphoid host response, and lymph node status did not significantly differ between the different histologic subtypes. Of all patients with ampullary adenoma only, there were 11 men and 20 women with a median age of 63 years at diagnosis (range: 37 to 84). Nineteen of 31 (61%) showed mild-to-moderate dysplasia (LGD) and 12/31 (39%) exhibited high-grade dysplasia.
MSI Status and Associated Tumor Morphology
Microsatellite analysis was successfully performed in 144 carcinomas of the ampulla of Vater and revealed a MSI-H phenotype in 15 cases (10%). Five tumors (4%) were MSI-L and 124 (86%) were MSS. MSI-L and MSS were combined into 1 group (''MSS'') for statistical analysis, because there were no statistical differences between the 2 groups for any of the parameters investigated (data not shown). Seven of 15 ampullary carcinomas with MSI-H (47%) exhibited an intestinal subtype, 4 were intestinal-mucinous, and 3 were pancreatobiliary. Additonally, 1 case was an invasive papillary carcinoma. The incidence of lymph node metastases in the MSI-H group was not significantly different compared with the MSS group. All 3 tumors with synchronous distant metastases (UICC IV) were MSS. For each category of microsatellite instability (MSS, MSI-L, MSI-H), the percentage of tumors that showed loss of a MMR protein was calculated ( Table 2 ). The sensitivity of the different microsatellite markers for detecting MMR deficiency confirmed by loss of MMR protein expression, ranged from 36% (APC) to 86% (D18S61) for dinucleotide markers and from 80% (BAT26) to 90% (BAT25) for mononucleotide markers. However, the specificity of the individual markers was very high, ranging from 94% (D18S61) to 100% (BAT25, BAT26, BAT40; Fig. 2 ). MSI-L was detected in 5/144 carcinomas (4%), 7/59 carcinoma-associated adenomas (12%), and 3/30 pure adenomas (10%), all exclusively due to 1 unstable dinucleotide repeat.
The following histologic parameters significantly differed between the MSI-H and the MSS group (for summary see Table 3 and Figs. 3A-D): histologic subtype (P = <0.001), high tumor grade (P = 0.013), mucinous features (presence vs. absence; P<0.001), growth pattern (infiltrative vs. expansive with pushing border; P = 0.044), and lymphoid host response (TILs: none vs. (15) 47 (7) 13 (2) 13 (2) 20 (3) rare/intense; P<0.001; peritumorous lymphocytes: none vs. rare/intense; P<0.001). Six of 15 MSI-H carcinomas (40%) had a Crohn's like reaction, whereas these characteristic lymphocyte aggregates were found only in 15/128 (12%) of MSS tumors (P = 0.010; Table 4 ). There was no significant correlation between MSI status and median age at diagnosis (MSS-group: 67 y; MSI-H group 68 y), sex, tumor stage, lymphatic and vascular invasion. MSI analysis was evaluable in 30/31 pure adenomas and in 59/89 carcinoma-associated adenomas. Eight adenomas were MSI-H, the remaining adenomas showed MSS (n = 71) and MSI-L (n = 10), respectively. MSI analysis from carcinoma-associated adenoma and the corresponding carcinoma could be compared in 54 cases. Concordant results were found in 6 of 8 MSI-H and 42 of 46 MSS cases, respectively. The adenomatous areas of the remaining 2 MSI-H and 4 MSS-tumors were MSI-L. None of the carcinoma-associated adenomas of MSI-H cancers was MSS and none of the carcinoma-associated adenomas of MSS cancer was MSI-H.
MMR Protein Expression
Expression of MMR proteins was evaluated by IHC. Both components of carcinomas with carcinoma-associated Figure 4B summarizes the number of cases with MLH1 promoter hypermethylation of adenomas and carcinomas depending on MLH1 protein expression and MSI status. MLH1 was hypermethylated in 3 adenomas (75%) and 5 (83%) carcinomas with loss of MLH1 expression, 1 MSI-H carcinoma-associated adenoma and 1 carcinoma showed no hypermethylation. Additionally, the MSI-H carcinoma that could not be analyzed by IHC also showed MLH1 hypermethylation. The carcinoma with normal MMR protein expression and high instability in dinucleotide repeat markers only, showed no hypermethylation. Furthermore, all MSS and MSI-L cancers (100%) with normal MLH1 protein expression were not hypermethylated.
Survival Analysis and Prognostic Factors Relation of Clinicopathologic and Histopathologic Characteristics and Patient Survival
The median survival time of 118 patients of ampullary carcinoma with complete follow-up data was 38 months. Forty-six remaining cases were not included in the survival analysis because their death (n = 7) was unrelated to cancer or because follow-up information was unavailable (n = 39). The difference in cumulative survival of the 5 histologic subtypes was statistically significant, as shown in Figure 5A . The mean survival time was 41 months (CI95: 25-57) for patients with pancreatobiliary subtype (n = 27), whereas it was 97 (CI95: 77-117) and 76 (CI95: 56-95) months for the patients with intestinal (n = 56) and intestinal-mucinous subtype (n = 13), respectively. Patients with invasive papillary carcinomas (n = 7) and with poorly differentiated adenocarcinomas (n = 15) had a mean survival time of 59 (CI95: 23-95) and 19 (CI95: 10-28) months, respectively. Lymph node metastases (P = 0.001), high tumor stage (>pT2; P<0.001), high stage of disease (UICCstage>IIA; P<0.001), high tumor grade (G3; P = 0.005), infiltrative growth pattern (P<0.001), lymphatic invasion (P = 0.009), and absence of TILs (P = 0.010) were associated with poor survival (Figs. 5C-E; Table 5 ). Univariate analysis showed no significant difference for the remaining parameters, including vascular invasion, peritumoral lymphocytes, Crohn's like reaction, and percentage of mucinous areas.
MSI Status and Survival
The prognostic value of MSI status was assessed by univariate analysis. The OS of MSI-H patients differed significantly from that of MSS patients (P = 0.008). The mean survival time of MSI-H patients was 88 months (CI95: 73-103) compared with 68 months (CI95: 53-84) in the non-MSI-H group (Fig. 5B) . For the multivariate analyses, the following nondichotomic parameters were dichotomized or grouped as follows: stage of disease (UICC-stage IA/IB/IIA vs. IIB vs. III/IV), tumor grade (G1/G2 vs. G3), TILs (none vs. rare/intense), and histologic subtype (intestinal/intestinal-mucinous vs. pancreatobiliary vs. other histologic subtypes). Tumor entity, tumor grade, stage of disease, and MSI status were independent prognostic factors in multivariate analysis using the Cox proportional hazards regression model for all variables that had been significant on univariate analysis. The results of multivariate analysis are summarized in Table 6 .
DISCUSSION
The development of ampullary carcinoma from adenomas as precancerous lesions has been well documented, . P values shown were calculated using the log-rank test for survival differences. MSI-H indicates high microsatellite instability; MSI-L, low microsatellite instability; MSS, microsatellite stable; UICC, International Union Against Cancer.
but studies investigating molecular alterations associated with the proposed adenoma-carcinoma sequence are scarce. 4, 20, 26, 28, 34, 35, 40, 41, 51, 52, [58] [59] [60] 77 Because of the infrequency of ampullary tumors many of these previous studies have been performed on relatively small numbers of cases, and did not take histologic subtypes and distinct histomorphologic features into account. The present study represents the largest series of ampullary carcinomas investigated up to now. The intestinal subtype (46.5%) predominated, followed by pancreatobiliary (23.5%), poorly differentiated (12.9%), intestinalmucinous (8.2%), and invasive papillary carcinomas (5.3%). This distribution is similar to the Memorial Sloan-Kettering Cancer Center series of 140 cases comprising 49% intestinal, 22% pancreatobiliary, 6% invasive papillary carcinomas, and 3% poorly differentiated adenocarcinomas. 7 Matsubayashi et al 51 reported 58% intestinal and 42% pancreatobiliary carcinomas (n = 52). In contrast, the series of Kimura et al 45 (n = 53) and Fischer and Zhou 27 (n = 55) showed a predominance of the pancreatobiliary subtype with 75% and 44% of cases, respectively, whereas only 25% and 23% intestinal carcinomas were described. These discrepancies in the morphologic classification reinforce the necessity to define new molecular or immunohistochemical markers and to standardize diagnostic criteria to distinguish different subtypes of tumors of the ampulla of Vater with different prognosis and possibly different response to treatment. In our series, we found a significantly better prognosis for patients with the intestinal-mucinous and intestinal subtype compared with invasive papillary, pancreatobiliary, and poorly differentiated adenocarcinomas (Fig. 5A) . In the study of Kimura et al 45 the outcome of the intestinal subtype was also significantly better than 27 failed to find even a tendency for improved cumulative survival comparing intestinal versus pancreatobiliary carcinomas. We based our classification on strict histomorphologic criteria and did not include IHC. Our data strongly suggest the existence of at least 2 histologic subgroups of tumors in the ampullary region, that is, the intestinal (-mucinous) and the pancreatobiliary type which have a different clinical outcome.
Of the clinicopathologic parameters analyzed, lymphatic invasion, lymph node metastases, high tumor stage (>pT2), high stage of diseases (UICC-stage>IIA), and high tumor grade (G3), were associated with poor survival. These findings were consistent with recently published studies investigating factors influencing the outcome of surgically treated ampullary and periampullary cancers. 11, 63, 79 Additionally, we could show that both infiltrative growth pattern and absence of TILs adversely influence OS (Figs. 5D-E) .
In an attempt to detect specific molecular changes correlated to the histologic subtype, we analyzed MSI-H status and MMR protein expression. Because there are no established criteria for assessing MSI-H in ampullary neoplasms, we used the consensus panel for HNPCC screening and an cut-off value Z30% of the markers tested for classifying a tumor as MSI-H, as recommended in the international guidelines for colorectal cancers.
14 In our study, 7% of pure adenomas and 10% of carcinomas revealed an MSI-H phenotype, accompanied by loss of MMR protein expression in 50% and 79% of cases, respectively. The few studies about ampullary neoplasms reported MSI-H in 0% of pure and carcinoma-associated adenomas and 12.5% to 22.2% of carcinomas. 5, 36, 76 58 The considerable discrepancies between these studies may be due to differences in the evaluation method, the number, and type of microsatellites analyzed and the cut-off used (for summary see Table 1 ). The lack of MMR protein expression has been found to be strongly associated with the MSI-H phenotype. 49 In CRC, marker selection has a significant effect on the determination of MSI status, 24 but no primer panel has been established for ampullary cancers so far. The immunohistochemical and histomorphologic results of this study support the use of the National Institutes of Health consensus panel for microsatellite analysis of colonic neoplasms as it allows the reliable detection of MSH-H ampullary carcinomas and associated precursor lesions. Seventy-three percent of cancers displayed concordant loss of MMR protein expression, respectively. Furthermore, all MSS and MSI-L cancers (n = 125) demonstrated strong nuclear staining with all 3 MMR proteins tested, and none of the adenomas associated with MSI-H cancer was MSS or of MSS-cancer was MSI-H. Interestingly, 7 of the 15 cases with MSI-H showed loss of MLH1. In sporadic colon cancer, loss of MLH1 expression is often due to promoter hypermethylation rather than a germline mutation. 21, 42, 83 In fact, in this study, MLH1 was hypermethylated in 3 ampullary adenomas (75%) and 5 carcinomas (83%) with loss of MLH1 expression. Our observation that hypermethylation and loss of MLH1 were already present in adenomatous tissue indicates that hypermethylation of the MLH1 promoter could be an early acquired epigenetic event in the ampullary adenoma-carcinoma sequence. Furthermore, the strong association between promoter hypermethylation and loss of MLH1 protein expression indicates that acquired hypermethylation is the main inactivation mechanism of this gene in ampullary tumors and suggests that germline mutations of MMR genes and HNPCC as a hereditary predisposition may not play a major role in these cancers.
In our series, only 4 cases with MSI-H displayed normal MMR protein expression. All of these were exclusively due to unstable dinucleotide repeats. These cases were 1 pure adenoma and 3 carcinomas (2 of which had an associated adenoma). Possible explanations for this finding include a mutation in a different MMR gene (eg, PMS2) or a MMR gene mutation resulting in expression of a nonfunctional or truncated MMR protein that can still be detected by IHC. An alternative explanation could be that the MSI-H status of these tumors that is restricted to denucleotide markers is in fact not associated with MMR protein deficiency. Interestingly, in a recent study of 1058 CRC, Xicola et al 84 also observed that all tumors that were classified as MSI-H due to mutated dinucleotide repeats only, were positive for MMR protein expression. When they examined an additional set of mononucleotide markers in these tumors, all of them were stable. Therefore, they discourage the use of dinucleotide repeats as markers to detect MMR protein deficiency. Our findings are in line with these observations except for 1 case with loss of MLH1 expression where MSI was restricted to dinucleotide repeat markers.
The frequency of MSI-H in sporadic ampullary cancer is therefore comparable with or somewhat higher than that reported in the few studies investigating biliary tract and pancreatic carcinomas. 3, 48, 56, 57, 64, 72, 76, 85 Compared with other gastrointestinal tumors, our data suggest that MSI-H in ampullary cancers is less frequent than in sporadic colorectal (13% to 16.5% 24, 80 ), gastric (31% to 38.5% 10, 43, 46 ) , and small bowel tumors (18% to 28.6% 16, 62 ). An additional important finding of the study was, that the MSI-H phenotype was significantly associated with both improved survival of patients and distinct, reproducible recognizable histomorphologic characteristics (summarized in Table 4 and Figs. 3A-D) . Interestingly, the majority of MSI-H tumors showed either an intestinal (-mucinous) morphology or tumor heterogeneity with mucinous areas. In addition, the tumors had poor differentiation, expansive growth pattern, and marked lymphoid host response. This distinct histomorphologic phenotype has also been described in both sporadic and HNPCC-related colorectal, gastric, and small bowel cancers with MSI-H. 9, 17, 39, 44, 65, 71, 86 Similarly to MSI-H CRC, 86 a higher mean percentage of mucin was a feature of the MSI-H group (mean 30%) compared with the MSS group (mean 3%). Moreover, a specific histologic pattern was also noted in relation to the MMR protein that is lost. MLH1 and isolated MSH6-negative tumors seem to be more likely mucinous than isolated MSH2 and combined MSH2 and MSH6 deficient ones (mean 33%, 45%, 10%, and 5%,). Interestingly, 2 out of 3 MSI-H, but only 1 out of 31 MSS pancreatobiliary carcinomas also showed a mucinous component (10% and 70% vs. 10%), which is usually only infrequently seen in this subtype. 7 The strict definition of mucinous carcinoma requiring pools of secretory mucin to comprise more than 50% of the tumor, may therefore lack sensitivity when it is used as a predictor of MSI-H. This finding may serve as an argument to describe any mucinous differentiation in the report, indicating the percentage of the area, which should be helpful to differentiate between MSS and MSI-H cases. 31 As previously described for MSI-H CRCs, 9, 17, 31, 39, 53, 73, 86, 88 MSI-H was significantly associated with intense TILs and peritumorous lymphocytes as well as Crohn's like reaction in our series of ampullary cancers.
In the present study, the survival rates of MSI-H patients were significantly better than those with MSS, as demonstrated by univariate and multivariate analyses. Most of the patients with MSH-H carcinomas showed concordant loss of MMR protein expression and MLH1 promoter hypermethylation. In cases with associated adenomas, the results in both the carcinomatous and adenomatous areas were identical, arguing for MLH1 hypermethylation, MMR deficiency, and MSI being early events in the molecular carcinogenesis of these tumors.
In conclusion, we present the largest histomorphologic, immunohistochemical, and molecular study of ampullary carcinomas and its precursor lesions published up to now. Our data clearly show that at least 2 histomorphologically different tumor subtypes, that is, the intestinal (-mucinous) and the pancreatobiliary type, exist with different clinical outcomes. A MMR deficient molecular pathway of carcinogenesis is associated with a significant percentage of the intestinal (-mucinous) subtype and characterized by specific histomorphologic features. Our findings indicate that the MSI-H phenotype and MLH1 hypermethylation develop at the stage of adenoma as an early event. Further studies to elucidate the molecular pathway of carcinogenesis of ampullary carcinomas and the clinical implications will be essential to optimize diagnosis, prognostication, and treatment.
